Skip to main content
    C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.46
    -0.01 (-1.08%)

    Market Cap: $13.59M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(16/33)
    Avg Surprise
    -72.85%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.05
    Range$-1.05 - $-1.05
    1 analysts
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.38
    Range$-0.38 - $-0.38
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current$-0.38
    Revenue Consensus
    $4M
    Range$4M - $4M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-1.05---
    Jun 26
    Reported Aug 14
    		$-0.34$-0.36+5.56%Beat+57.5%
    Mar 26
    Reported May 15
    		$-0.95$-0.32-196.88%Miss+25.2%
    Dec 25
    Reported Feb 13
    		$-0.38$-0.30-26.67%Miss+70.8%
    Sep 25
    Reported Dec 25
    		$-0.11N/A+54.17%Beat+98.1%
    Jun 25
    Reported Aug 12
    		$-0.80$-0.21-280.95%Miss+46.7%
    Mar 25
    Reported May 14
    		$-1.27$0.11-1254.55%Miss-1.6%
    Dec 24
    Reported Jan 3
    		$-1.30$-1.25-4.00%Miss-2066.7%
    Sep 24
    Reported Dec 27
    		$-5.80$-1.50-286.67%Miss-231.4%
    Jun 24
    Reported Aug 12
    		$-1.50$-1.12-33.93%Miss+0.0%
    Mar 24
    Reported May 14
    		$-1.25$-1.50+16.67%Beat+28.6%
    Dec 23
    Reported Feb 14
    		$-0.06N/A-146.15%Miss-200.0%
    Sep 23
    Reported Dec 29
    		$-1.75$-1.50-16.67%Miss-40.0%
    Jun 23
    Reported Aug 14
    		$-1.50$-1.75+14.29%Beat+0.0%
    Mar 23
    Reported May 12
    		$-1.75$-1.25-40.00%Miss-40.0%
    Dec 22
    Reported Feb 10
    		$-0.02N/A+66.67%Beat+98.7%
    Sep 22
    Reported Dec 22
    		$-1.25$-1.50+16.67%Beat-6150.0%
    Jun 22
    Reported Aug 11
    		$-1.50$-1.50+0.00%Beat-20.0%
    Mar 22
    Reported May 12
    		$-1.25$-1.75+28.57%Beat-25.0%
    Dec 21
    Reported Feb 10
    		$-1.50$-1.50+0.00%Beat-900.0%
    Sep 21
    Reported Dec 15
    		$-0.02$-0.04+50.00%Beat+98.9%
    Jun 21
    Reported Aug 12
    		$-1.25$-1.00-25.00%Miss+54.5%
    Mar 21
    Reported May 13
    		$-1.00N/A+55.56%Beat+69.2%
    Dec 20
    Reported Feb 11
    		$-0.15$0.16-193.75%Miss+96.0%
    Sep 20
    Reported Dec 16
    		$-1.75$-2.50+30.00%Beat-993.8%
    Jun 20
    Reported Aug 14
    		$-2.75$-2.75+0.00%Beat+45.0%
    Mar 20
    Reported May 14
    		$-3.25$-2.75-18.18%Miss+35.0%
    Dec 19
    Reported Feb 13
    		$-3.75$-3.50-7.14%Miss+31.8%
    Sep 19
    Reported Dec 16
    		$-0.16$-0.14-14.29%Miss+0.0%
    Jun 19
    Reported Aug 14
    		$-5.00$-1.50-233.33%Miss-5.3%
    Mar 19
    Reported May 15
    		$-5.00$-5.00+0.00%Beat-1036.4%
    Dec 18
    Reported Feb 14
    		$-5.50$-5.25-4.76%Miss-1347.4%
    Sep 18
    Reported Dec 11
    		$-0.16$-0.16+0.00%Beat+62.8%
    Jun 18
    Reported Aug 14
    		$-4.75$-8.00+40.63%Beat-869.4%
    Mar 18
    Reported May 11
    		$-0.44N/AN/ABeat+20.0%
    Dec 17
    Reported Mar 20
    		$-0.38N/AN/ABeat+96.6%
    Sep 17
    Reported Dec 13
    		$-0.43N/AN/ABeat-
    Jun 17
    Reported Aug 14
    		$-0.49N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-0.55N/AN/ABeat-
    Dec 16
    Reported Feb 14
    		$-11.09N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.26EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-670.00%
    ROE-81.10%ROIC-84.31%
    Financial Health
    Debt/Equity0.10xInterest Coverage-119.35x
    Current Ratio0.84xQuick Ratio0.40x
    Trading Statistics
    Beta1.00Avg Volume187.46K
    52-Week High$2.1952-Week Low$0.46

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.49
    SMA 20$0.53
    SMA 50$0.58
    SMA 200$0.68
    EMA 10$0.49
    EMA 20$0.52
    EMA 50$0.56
    EMA 200$0.70

    MACD

    Line: -0.03Signal: -0.03Hist: -0.01

    ADX

    ADX: 22.9+DI: 13.1-DI: 22.2

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down96.0
    PSAR$0.55

    Bollinger Bands

    Upper Band$0.62
    Lower Band$0.44
    %B Position3366%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    33.5

    Momentum Oscillators

    Stoch %K9.7
    Stoch %D10.8
    Williams %R-92.9
    ROC (10d)-14.8%
    Momentum-0.08
    CCI (20d)-114.0
    MFI (14d)28.3

    Volatility Measures

    ATR (14d)$0.03(7.5%)
    StdDev (20d)0.04
    Hist Vol50.8%(High)

    Volume Flow

    VWAP$0.47
    OBV100.8M
    AD Line-57.6M
    CMF (20d)-0.321

    Volume Metrics

    Avg Vol (20d)186.9K
    Vol Ratio1.6x(High)
    VWMA (20d)$0.53

    Pivot Points

    R3$0.49
    R2$0.48
    R1$0.47
    Pivot Point$0.46
    S1$0.45
    S2$0.44
    S3$0.43

    Advanced Oscillators

    TSI-23.54
    Ultimate Osc37.0
    KST-153.92

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.49M$1.67M$3.94M$0$0$0$0$155,926$0$0$0$0
    Cost of Revenue$491,843$328,878$789,208$62,038$0$0$0$155,926$0$0$0$49,969
    Gross Profit$1.00M$1.34M$3.15M$-62,038$0$0$0$-53,685$0$0$0$-49,969
    Operating Expenses$12.73M$33.53M$12.17M$8.44M$8.79M$11.26M$10.04M$11.05M$10.63M$10.97M$9.34M$10.12M
    R&D$2.77M$3.35M$2.17M$1.64M$1.62M$3.77M$2.13M$2.91M$2.76M$3.61M$2.62M$2.88M
    SG&A$6.15M$26.39M$5.72M$3.91M$4.45M$4.79M$5.39M$5.49M$4.81M$4.29M$3.66M$4.17M
    Operating Income$-11,732,074$-32,194,786$-9,019,208$-8,437,309$-8,788,007$-11,260,678$-10,039,614$-11,050,478$-10,634,179$-10,970,201$-9,340,823$-10,124,723
    Interest Income$116,691$3.89M$45,097$53,423$20,637$13,413$22,608$117,314$204,843$182,205$253,638$324,813
    Interest Expense$231,732$33,031$155,538$42,097$172,262$0$0$0$0$0$0$0
    Income Before Tax$-12,026,607$-28,340,956$-9,129,649$-8,479,406$-8,939,632$-11,247,265$-10,017,006$-10,933,164$-10,429,336$-8,400,154$-9,087,185$-9,799,910
    Income Tax Expense$-107,347$-231,210$264,240$264,240$264,240$264,240$264,240$144,000$144,000$144,000$144,000$144,000
    Net Income$-11,919,260$-28,109,746$-9,393,889$-8,743,646$-9,203,872$-11,511,505$-10,281,246$-11,077,164$-10,573,336$-8,544,154$-9,231,185$-9,943,910
    EBITDA$-9,970,283$-30,433,815$-8,462,253$-8,375,271$-8,746,640$-11,204,668$-9,984,779$-10,996,793$-10,581,331$-8,530,289$-9,289,815$-10,074,754
    EBIT$-11,911,566$-32,194,786$-9,019,208$-8,437,309$-8,788,007$-11,260,678$-10,039,614$-11,050,478$-10,634,179$-8,582,359$-9,340,823$-10,124,723
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTXR

    News

    Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

    Citius Pharmaceuticals announced its participation in investor conferences scheduled for October 2026. The company will likely present updates on its pharmaceutical pipeline and engage with the investment community at...

    Moomoo•10/13/26•Neutral

    Citius Pharmaceuticals stock carries LYMPHIR into fiscal Q3

    Citius Pharmaceuticals (CTXR) stock closed at USD 0.52 on October 5, 2026, driven by its LYMPHIR commercialization. The company reported USD 1.5 million in fiscal Q3 2026 revenue and USD 7.1 million for the first nine...

    AD HOC NEWS•10/6/26•Somewhat-Bullish

    Citius Pharmaceuticals stock reports USD 7.1 million LYMPHIR revenue

    Citius Pharmaceuticals reported $7.1 million in LYMPHIR revenue within nine months of its commercial ramp, with 44 institutions and 135 health plans adopting the oncology drug. LYMPHIR shows a 77% gross margin...

    AD HOC NEWS•10/1/26•Bullish

    Citius Pharmaceuticals stock trades quietly as investors await next catalysts

    Citius Pharmaceuticals stock is trading quietly as investors assess recent clinical and financial milestones. The company's focus on advancing critical care and oncology therapies means ongoing operating expenses and R&D...

    AD HOC NEWS•9/18/26•Neutral

    Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    Citius Pharmaceuticals (CTXR) has received an extension from Nasdaq until February 8, 2027, to regain compliance with the $1.00 minimum bid price rule. To meet this requirement...

    TradingView•8/21/26•Bearish

    CTXR Valuation and Fair Value

    P/E
    -0.3x
    Forward P/E
    0.3x
    PEG
    0.0x
    P/B
    0.2x
    See GNG's fair value

    CTXR Profitability: Margins, ROIC and FCF

    Operating margin
    -670.0%
    Net margin
    0.0%
    ROIC
    -84.3%
    ROE
    -81.1%
    FCF margin
    -490.7%

    CTXR Competitors

    CompanyTicker
    SINTX Technologies IncSINT
    Vyome Holdings, Inc.HIND
    Estrella Immunopharma Inc.ESLA
    Tvardi Therapeutics, Inc.TVRD
    Pasithea Therapeutics CorpKTTA
    Biofrontera IncBFRI
    Dare Bioscience IncDARE
    Femasys IncFEMY

    Sector: Healthcare

    CTXR Bull Case vs Bear Case

    Bear case

    • CTXR beat EPS estimates in 25.0% of its last 8 reported quarters.

    CTXR Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -248.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.05

    Frequently Asked Questions About CTXR

    Does CTXR pay dividends?

    Citius Pharmaceuticals Inc (CTXR) does not currently pay a regular dividend.

    What is CTXR's market cap?

    Citius Pharmaceuticals Inc (CTXR) has a market capitalization of $13.59M with a current stock price of $0.46.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In